RE:RE:RE:RE:1 Year ago today ! CancerSlayer, thank's for the clarifications, people tend to forget about the difficult journey TLT had to go through to get were we are.
About Anktiva (ImmunityBio).
1)Anktiva is a 14 months long maintenance therapy, that doesn't even cure the cancer.
2)Anktiva doesn't even come close to being as good as TLT-Ruvidar.
In spite of the above,the FDA gave Anktiva BTD approval(Dec 4,2019),...
-1 month after the FDA BTD approval, ImmunityBio(Anktiva) SP was at $6.00US($8.00CAN).
-8 months after the FDA BTD approval ImmunityBio SP was at $14.00US($20.00CAN).
-14 months after the FDA BTD approval, the SP was at $40.00US($56.00Can).
After that ImmunityBio SP went back down..because they had issues with the FDA.
1) TLT-Ruvidar is much superior to Anktiva(ImmunityBio).
2) TLT has a much stronger pipeline of future products than ImmunityBio.
3) Ruvidar will not have the same issues with the FDA as Anktiva(because Ruvidar is easier to produce and has a very long shelf life).
With all the above advantages of TLT-Ruvidar over Anktiva, it will be very interesting to see were TLT SP wil climb to after the FDA BTD approval of Ruvidar.
I love my TLT shares.
CancerSlayer wrote: Oden6570 wrote: How long would the wait be if we were not on Fast Track ? Cannot imagine it being any slower than this has been moving.
I believe the pandemic, limited budget & limited number of trial sites (as well as the more gradual onboarding of US sites) significantly impacted trial speed & progress. Enrollment hit a snag during the pandemic & it's generally more difficult to enroll patients when you have relatively few(er) clinical trial sites. The Anktiva trial & its significantly larger budget had 32 trial sites. Unfortunately, the fast track designation can lose its splendor when faced with the above...all imo.